Bristol Myers (BMY) announces 1st data from Zenbexus with Daratumumab, Phase 3 showed a statistically significant and clinically meaningful improvement in minimal residual disease-negative complete response rate

Positive Phase 3 readouts in established hematology franchises follow a familiar sequence: the stock reaction is typically sized by whether the data expand an addressable population or merely defend an existing one, and a minimal residual disease-negative complete response endpoint sits in the former camp, since MRD negativity has increasingly functioned as a surrogate that regulators and payers have been willing to reward. Combination data built on an entrenched backbone agent tend to be read as franchise-extending rather than novel, which historically caps the upside move relative to first-in-class readouts but also reduces the risk of full retracement on later scrutiny. The points worth watching are the full dataset presentation at the next major hematology meeting, where depth of response and durability separate practice-changing results from statistically significant but commercially modest ones, and any regulatory filing language, since an sBLA pathway converts the data into revenue timing. Comparator arm detail and subgroup consistency are the usual tells for how guideline committees will treat it. Peer read-through has tended to concentrate in other myeloma-exposed names rather than the broader large-cap pharma complex.